BioCentury | Sep 12, 2019
Company News

Anokion raises $40M series B, grabs back programs from spinout

...$40 million in a series B round, autoimmune company Anokion said Wednesday it will acquire Kanyos...
...Geraghty told BioCentury. At Kanyos’ launch, Astellas had an option to acquire the company, and Kanyos...
...who is CEO of Anokion and Kanyos. Terms of the acquisition are not disclosed. Acquiring Kanyos...
BioCentury | Jan 25, 2019
Product R&D

Rubius turns immunotherapy red

...a bioreactor." Pablo Cagnoni, Rubius Therapeutics At least two companies, Anokion S.A. and its spinout Kanyos Bio Inc....
...MS therapy and has partnered with Celgene Corp. to develop therapies for undisclosed autoimmune diseases. Kanyos...
...Anokion S.A., Ecublens, Switzerland Astellas Pharma Inc. (JASDAQ:4503), Tokyo, Japan Celgene Corp. (NASDAQ:CELG), Summit, N.J. Kanyos Bio Inc....
BioCentury | May 23, 2016
Finance

Venturing west

...which develops therapeutics that affect mitochondrial function, immuno-oncology play Potenza Therapeutics Inc. and autoimmune company Kanyos Bio Inc....
BioCentury | Sep 10, 2015
Distillery Techniques

Techniques: Conjugation of glycophorin A (GYPA)-binding peptides to protein drugs to reduce anti-drug immunity

...asparaginase is marketed as a generic to treat acute lymphoblastic leukemia (ALL). Anokion S.A. and Kanyos Bio Inc....
...protein drugs to reduce anti-drug immunity LICENSING STATUS: Patent pending; licensed to Anokion S.A. and Kanyos Bio Inc....
BioCentury | Jun 8, 2015
Financial News

Kanyos completes venture financing

Kanyos Bio Inc. , Cambridge, Mass. Business: Autoimmune, Endocrine/Metabolic Date completed: 2015-06-02 Type: Venture financing Raised: $16 million Investors: Astellas Pharma Inc. ; Versant Ventures ; Novo Ventures; Novartis Venture Funds; and other undisclosed investors WIR...
BioCentury | Jun 8, 2015
Company News

Kanyos, Astellas deal

...partnered with and invested in Kanyos, a newco spun out from Anokion S.A. (Ecublens, Switzerland). Kanyos...
...disease. Astellas will provide R&D funding for Kanyos’ programs and has an option to acquire Kanyos...
...programs and has an option to acquire Kanyos once its programs meet undisclosed preclinical milestones. Kanyos...
BioCentury | Jun 3, 2015
Company News

Anokion spinout Kanyos partners with Astellas

...Kanyos Bio Inc. (Cambridge, Mass.), a newco spun out from Anokion S.A. (Ecublens, Switzerland). Astellas invested in Kanyos'...
...disease. Astellas will supply R&D funding for Kanyos' programs, and has an option to acquire Kanyos...
...programs, and has an option to acquire Kanyos once its programs reach undisclosed preclinical milestones. Kanyos...
Items per page:
1 - 7 of 7
BioCentury | Sep 12, 2019
Company News

Anokion raises $40M series B, grabs back programs from spinout

...$40 million in a series B round, autoimmune company Anokion said Wednesday it will acquire Kanyos...
...Geraghty told BioCentury. At Kanyos’ launch, Astellas had an option to acquire the company, and Kanyos...
...who is CEO of Anokion and Kanyos. Terms of the acquisition are not disclosed. Acquiring Kanyos...
BioCentury | Jan 25, 2019
Product R&D

Rubius turns immunotherapy red

...a bioreactor." Pablo Cagnoni, Rubius Therapeutics At least two companies, Anokion S.A. and its spinout Kanyos Bio Inc....
...MS therapy and has partnered with Celgene Corp. to develop therapies for undisclosed autoimmune diseases. Kanyos...
...Anokion S.A., Ecublens, Switzerland Astellas Pharma Inc. (JASDAQ:4503), Tokyo, Japan Celgene Corp. (NASDAQ:CELG), Summit, N.J. Kanyos Bio Inc....
BioCentury | May 23, 2016
Finance

Venturing west

...which develops therapeutics that affect mitochondrial function, immuno-oncology play Potenza Therapeutics Inc. and autoimmune company Kanyos Bio Inc....
BioCentury | Sep 10, 2015
Distillery Techniques

Techniques: Conjugation of glycophorin A (GYPA)-binding peptides to protein drugs to reduce anti-drug immunity

...asparaginase is marketed as a generic to treat acute lymphoblastic leukemia (ALL). Anokion S.A. and Kanyos Bio Inc....
...protein drugs to reduce anti-drug immunity LICENSING STATUS: Patent pending; licensed to Anokion S.A. and Kanyos Bio Inc....
BioCentury | Jun 8, 2015
Financial News

Kanyos completes venture financing

Kanyos Bio Inc. , Cambridge, Mass. Business: Autoimmune, Endocrine/Metabolic Date completed: 2015-06-02 Type: Venture financing Raised: $16 million Investors: Astellas Pharma Inc. ; Versant Ventures ; Novo Ventures; Novartis Venture Funds; and other undisclosed investors WIR...
BioCentury | Jun 8, 2015
Company News

Kanyos, Astellas deal

...partnered with and invested in Kanyos, a newco spun out from Anokion S.A. (Ecublens, Switzerland). Kanyos...
...disease. Astellas will provide R&D funding for Kanyos’ programs and has an option to acquire Kanyos...
...programs and has an option to acquire Kanyos once its programs meet undisclosed preclinical milestones. Kanyos...
BioCentury | Jun 3, 2015
Company News

Anokion spinout Kanyos partners with Astellas

...Kanyos Bio Inc. (Cambridge, Mass.), a newco spun out from Anokion S.A. (Ecublens, Switzerland). Astellas invested in Kanyos'...
...disease. Astellas will supply R&D funding for Kanyos' programs, and has an option to acquire Kanyos...
...programs, and has an option to acquire Kanyos once its programs reach undisclosed preclinical milestones. Kanyos...
Items per page:
1 - 7 of 7